Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHORIONIC GONADOTROPIN vs ELAGOLIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chorionic gonadotropin (h CG) binds to the luteinizing hormone/choriogonadotropin receptor (LHCGR) on the surface of gonadal cells, stimulating steroidogenesis and gametogenesis. In females, it triggers ovulation and luteinization; in males, it stimulates Leydig cells to produce testosterone.
Gonadotropin-releasing hormone (Gn RH) receptor antagonist that competitively binds to Gn RH receptors in the anterior pituitary, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, thereby suppressing ovarian estradiol production.
FDA-approved: Induction of ovulation in infertile females (as part of controlled ovarian hyperstimulation),FDA-approved: Treatment of prepubertal cryptorchidism,FDA-approved: Treatment of hypogonadotropic hypogonadism in males,Off-label: Weight loss (not recommended),Off-label: In vitro fertilization protocols
Management of moderate to severe pain associated with endometriosis
For hypogonadotropic hypogonadism: 1000-2000 IU subcutaneously or intramuscularly 2-3 times per week. For ovulation induction: 5000-10,000 IU intramuscularly as a single dose.
200 mg orally twice daily
Biphasic: initial half-life ~11 hours, terminal half-life ~23–30 hours. Single-dose half-life ~32 hours; repeated dosing may extend due to accumulation.
Terminal elimination half-life is approximately 4–6 hours. Clinical context: Steady state achieved within 5 days; tid dosing maintains therapeutic concentrations.
Primarily metabolized in the liver via proteolytic degradation; undergoes renal excretion with a half-life of 24-36 hours.
Primarily metabolized by CYP3A4; minor contribution from CYP2D6 and CYP2C8.
Primarily renal; intact h CG is excreted in urine. Negligible biliary/fecal elimination.
Renal (approximately 70% as unchanged drug and metabolites), fecal (approximately 30%)
Approximately 80% bound; binds to albumin and sex hormone-binding globulin (SHBG) with low affinity.
Approximately 99% bound to albumin and alpha-1-acid glycoprotein
0.3–0.5 L/kg; distributes into extracellular fluid, gonadal tissues, and poorly into fat.
Vd/F is approximately 40–60 L (0.5–0.8 L/kg). Clinical meaning: Extensive tissue distribution, consistent with a large volume of distribution.
IM/SC: ~40% to 100% (mean ~78%) due to variable absorption; IV: 100% (not typical). Oral: negligible (<1% due to degradation).
Oral: Approximately 30% (low due to first-pass metabolism); food increases exposure by approximately 30%.
No specific dose adjustment guidelines available; use with caution in severe renal impairment (GFR <30 m L/min/1.73 m²).
e GFR 30-89 m L/min: no adjustment. e GFR 15-29 m L/min: 100 mg twice daily. e GFR <15 m L/min: not recommended.
No specific dose adjustment guidelines available; use with caution in severe hepatic impairment (Child-Pugh class C).
Child-Pugh A: no adjustment. Child-Pugh B: 100 mg twice daily. Child-Pugh C: not recommended.
Cryptorchidism: 500-1000 IU subcutaneously or intramuscularly 2-3 times per week for 6 weeks. Delayed puberty: 500-1500 IU subcutaneously or intramuscularly 2-3 times per week.
Not established; safety and efficacy in pediatric patients have not been studied.
No specific dose adjustments; monitor for fluid retention and cardiovascular effects.
No specific dose adjustment required; clinical studies included limited patients ≥65 years, but no differences in safety or efficacy observed.
None. However, use in females requires careful monitoring to avoid ovarian hyperstimulation syndrome (OHSS), which can be severe.
None
Ovarian hyperstimulation syndrome (OHSS): Risk of severe OHSS with ascites, pleural effusion, and thromboembolic events,Multiple pregnancy: Increased risk due to ovulation induction,Thromboembolic events: Increased risk, especially in patients with prior history,Ovarian enlargement: Monitor with ultrasound,Hormonal-dependent malignancies: Caution in patients with prior history
Hepatic transaminase elevations: monitor liver function before and during treatment; discontinue if elevation >3x ULN or if signs of liver injury occur.,Bone density loss: monitor bone mineral density with long-term use; consider additional calcium/vitamin D.,Mood changes: increased risk of depression, suicidal ideation; monitor for new or worsening symptoms.,Altered menstrual bleeding; exclude pregnancy before starting.,Risk of osteoporosis with prolonged use.
Pregnancy,Primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Active thromboembolic disorder,Hormone-sensitive tumors (e.g., prostate, breast, ovarian),Hypersensitivity to h CG or any component
Known hypersensitivity to elagolix or any excipients,Concomitant use with strong organic anion-transporting polypeptide (OATP) 1B1 inhibitors (e.g., cyclosporine, gemfibrozil),Pregnancy, or women of reproductive potential not using effective contraception,Existing osteoporosis or severe bone loss,History of suicidal ideation or behavior
No known food interactions.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and may increase elagolix levels. No other food restrictions.
Chorionic gonadotropin is a pregnancy hormone; exogenous use during first trimester may theoretically alter placental hormone balance, but no increased risk of congenital anomalies has been established. However, use during pregnancy is contraindicated except as part of assisted reproductive technology protocols where its role is physiological. No fetal risks documented from therapeutic use in second or third trimester.
First trimester: High risk of pregnancy loss and major birth defects based on animal data and mechanism of action. Second and third trimesters: Contraindicated due to potential for harm. Elagolix is contraindicated in pregnancy.
Chorionic gonadotropin is not orally bioavailable and is likely degraded in infant gastrointestinal tract. Excretion into breast milk is unknown; M/P ratio not established. However, due to its protein nature, transfer is expected to be minimal. Use during breastfeeding is not recommended unless clearly necessary; theoretical risk of hormonal effects on infant.
Elagolix is excreted in animal milk; no human data. M/P ratio unknown. Not recommended during breastfeeding.
No pharmacokinetic dose adjustments are recommended in pregnancy as the drug is typically administered only prior to conception or in early pregnancy for luteal phase support. The endogenous hormone levels in pregnancy far exceed exogenous doses. No dose modification required in later trimesters because use is contraindicated.
No dose adjustments studied; contraindicated in pregnancy. No data on PK changes requiring dose modification.
Chorionic gonadotropin (h CG) is used to trigger ovulation in assisted reproduction and to treat hypogonadotropic hypogonadism in males. Monitor for ovarian hyperstimulation syndrome (OHSS) in women; discontinue if severe. Do not use in women with primary ovarian failure. In males, may cause gynecomastia or fluid retention.
Elagolix is an oral Gn RH antagonist for endometriosis-associated pain. Monitor bone mineral density (BMD) with dual-energy X-ray absorptiometry (DXA) if using >12 months or in patients with osteoporosis risk. Avoid use with strong CYP3A inducers (e.g., rifampin) or inhibitors (e.g., ketoconazole). May reduce efficacy of hormonal contraceptives. Assess pregnancy status before starting due to teratogenicity.
Report abdominal pain, bloating, nausea, vomiting, or rapid weight gain (signs of OHSS).,In males, report breast tenderness or swelling, or fluid retention (swollen ankles/feet).,Do not use if pregnant or breastfeeding unless directed by a specialist.,For fertility: timing of intercourse or IUI is critical; follow cycle monitoring closely.,In males: take as prescribed for testicular descent or hypogonadism; may require multiple doses.
Take elagolix at the same time daily with or without food.,Avoid grapefruit or grapefruit juice during treatment.,Use non-hormonal contraception (e.g., condoms) because elagolix may reduce hormonal contraceptive effectiveness.,Report severe headaches, vision changes, or heavy bleeding promptly.,Do not take elagolix if pregnant or planning to become pregnant; use effective birth control.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHORIONIC GONADOTROPIN vs ELAGOLIX, answered by our medical review team.
CHORIONIC GONADOTROPIN is a Gonadotropin Hormone that works by Chorionic gonadotropin (h CG) binds to the luteinizing hormone/choriogonadotropin receptor (LHCGR) on the surface of gonadal cells, stimulating steroidogenesis and gametogenesis. In females, it triggers ovulation and luteinization; in males, it stimulates Leydig cells to produce testosterone.. ELAGOLIX is a Gonadotropin-Releasing Hormone Antagonist that works by Gonadotropin-releasing hormone (Gn RH) receptor antagonist that competitively binds to Gn RH receptors in the anterior pituitary, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, thereby suppressing ovarian estradiol production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHORIONIC GONADOTROPIN and ELAGOLIX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHORIONIC GONADOTROPIN is: For hypogonadotropic hypogonadism: 1000-2000 IU subcutaneously or intramuscularly 2-3 times per week. For ovulation induction: 5000-10,000 IU intramuscularly as a single dose.. The standard adult dose of ELAGOLIX is: 200 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHORIONIC GONADOTROPIN and ELAGOLIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHORIONIC GONADOTROPIN is classified as Category C. Chorionic gonadotropin is a pregnancy hormone; exogenous use during first trimester may theoretically alter placental hormone balance, but no increased risk of congenital anomalies. ELAGOLIX is classified as Category C. First trimester: High risk of pregnancy loss and major birth defects based on animal data and mechanism of action. Second and third trimesters: Contraindicated due to potential for. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.